These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 12937659)
1. Progress in antibacterial and antifungal chemotherapy. Fromtling RA; Drug News Perspect; 2000 Aug; 13(6):366-77. PubMed ID: 12937659 [TBL] [Abstract][Full Text] [Related]
2. Human mycoses and advances in antifungal therapy. Fromtling RA Drug News Perspect; 2001 Apr; 14(3):181-92. PubMed ID: 12819825 [TBL] [Abstract][Full Text] [Related]
3. Advances in antifungal chemotherapy. Fromtling RA Drug News Perspect; 1998 Nov; 11(9):582-95. PubMed ID: 15616671 [TBL] [Abstract][Full Text] [Related]
4. Medical mycology and current trends in antifungal chemotherapy. Fromtling RA Drug News Perspect; 1998 Jun; 11(5):310-9. PubMed ID: 15616652 [TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312 [TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613 [TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Li L; Wang Z; Li R; Luo S; Sun X Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669 [TBL] [Abstract][Full Text] [Related]
10. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). ; Böhme A; Ruhnke M; Buchheidt D; Cornely OA; Einsele H; Enzensberger R; Hebart H; Heinz W; Junghanss C; Karthaus M; Krüger W; Krug U; Kubin T; Penack O; Reichert D; Reuter S; Silling G; Südhoff T; Ullmann AJ; Maschmeyer G Ann Hematol; 2009 Feb; 88(2):97-110. PubMed ID: 18853161 [TBL] [Abstract][Full Text] [Related]
11. Strategies for managing systemic fungal infection and the place of itraconazole. Potter M J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634 [TBL] [Abstract][Full Text] [Related]
12. The search for new antifungal drugs and strategies continues. Jack DB Drug News Perspect; 1998 Jun; 11(5):306-9. PubMed ID: 15616651 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of oral Candida to seven antifungal agents. Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594 [TBL] [Abstract][Full Text] [Related]
14. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Steinbach WJ; Stevens DA; Denning DW Clin Infect Dis; 2003 Oct; 37 Suppl 3():S188-224. PubMed ID: 12975752 [TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Kaya AD; Kiraz N Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704 [TBL] [Abstract][Full Text] [Related]
16. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Swinne D; Watelle M; Van der Flaes M; Nolard N Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180 [TBL] [Abstract][Full Text] [Related]
17. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. Lacroix C; de Chauvin MF J Antimicrob Chemother; 2008 Apr; 61(4):835-7. PubMed ID: 18218642 [TBL] [Abstract][Full Text] [Related]
19. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780 [TBL] [Abstract][Full Text] [Related]
20. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis. Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]